Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline : evidence-based advances in monitoring and treatment. / de Boer, Ian H.; Caramori, M. Luiza; Chan, Juliana C.N.; Heerspink, Hiddo J.L.; Hurst, Clint; Khunti, Kamlesh; Liew, Adrian; Michos, Erin D.; Navaneethan, Sankar D.; Olowu, Wasiu A.; Sadusky, Tami; Tandon, Nikhil; Tuttle, Katherine R.; Wanner, Christoph; Wilkens, Katy G.; Zoungas, Sophia; Lytvyn, Lyubov; Craig, Jonathan C.; Tunnicliffe, David J.; Howell, Martin; Tonelli, Marcello; Cheung, Michael; Earley, Amy; Rossing, Peter.

I: Kidney International, Bind 98, Nr. 4, 10.2020, s. 839-848.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

de Boer, IH, Caramori, ML, Chan, JCN, Heerspink, HJL, Hurst, C, Khunti, K, Liew, A, Michos, ED, Navaneethan, SD, Olowu, WA, Sadusky, T, Tandon, N, Tuttle, KR, Wanner, C, Wilkens, KG, Zoungas, S, Lytvyn, L, Craig, JC, Tunnicliffe, DJ, Howell, M, Tonelli, M, Cheung, M, Earley, A & Rossing, P 2020, 'Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment', Kidney International, bind 98, nr. 4, s. 839-848. https://doi.org/10.1016/j.kint.2020.06.024

APA

de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadusky, T., Tandon, N., Tuttle, K. R., Wanner, C., Wilkens, K. G., Zoungas, S., Lytvyn, L., Craig, J. C., Tunnicliffe, D. J., ... Rossing, P. (2020). Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney International, 98(4), 839-848. https://doi.org/10.1016/j.kint.2020.06.024

Vancouver

de Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K o.a. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney International. 2020 okt.;98(4):839-848. https://doi.org/10.1016/j.kint.2020.06.024

Author

de Boer, Ian H. ; Caramori, M. Luiza ; Chan, Juliana C.N. ; Heerspink, Hiddo J.L. ; Hurst, Clint ; Khunti, Kamlesh ; Liew, Adrian ; Michos, Erin D. ; Navaneethan, Sankar D. ; Olowu, Wasiu A. ; Sadusky, Tami ; Tandon, Nikhil ; Tuttle, Katherine R. ; Wanner, Christoph ; Wilkens, Katy G. ; Zoungas, Sophia ; Lytvyn, Lyubov ; Craig, Jonathan C. ; Tunnicliffe, David J. ; Howell, Martin ; Tonelli, Marcello ; Cheung, Michael ; Earley, Amy ; Rossing, Peter. / Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline : evidence-based advances in monitoring and treatment. I: Kidney International. 2020 ; Bind 98, Nr. 4. s. 839-848.

Bibtex

@article{a32819d8a9b6425ea8dcab4a1079aeb9,
title = "Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment",
abstract = "The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeutics offer new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. An enlarging base of high-quality evidence from randomized clinical trials is available to evaluate important new treatments offering organ protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The goal of the new guideline is to provide evidence-based recommendations to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies. In addition, the guideline contains practice points to facilitate implementation when insufficient data are available to make well-justified recommendations or when additional guidance may be useful for clinical application. The guideline covers comprehensive care of patients with diabetes and CKD, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and self-management and health systems approaches to management of patients with diabetes and CKD.",
keywords = "angiotensin II receptor blocker, angiotensin-convering enzyme inhibitor, chronic kidney disease, dialysis, evidence-based, GLP-1 receptor agonist, glycemia, glycemic monitoring, glycemic targets, guideline, HbA1c, hemodialysis, KDIGO, lifestyle, metformin, models of care, nutrition, renin-angiotensin system, self-management, SGLT2 inhibitor, systematic review, team-based care",
author = "{de Boer}, {Ian H.} and Caramori, {M. Luiza} and Chan, {Juliana C.N.} and Heerspink, {Hiddo J.L.} and Clint Hurst and Kamlesh Khunti and Adrian Liew and Michos, {Erin D.} and Navaneethan, {Sankar D.} and Olowu, {Wasiu A.} and Tami Sadusky and Nikhil Tandon and Tuttle, {Katherine R.} and Christoph Wanner and Wilkens, {Katy G.} and Sophia Zoungas and Lyubov Lytvyn and Craig, {Jonathan C.} and Tunnicliffe, {David J.} and Martin Howell and Marcello Tonelli and Michael Cheung and Amy Earley and Peter Rossing",
year = "2020",
month = oct,
doi = "10.1016/j.kint.2020.06.024",
language = "English",
volume = "98",
pages = "839--848",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline

T2 - evidence-based advances in monitoring and treatment

AU - de Boer, Ian H.

AU - Caramori, M. Luiza

AU - Chan, Juliana C.N.

AU - Heerspink, Hiddo J.L.

AU - Hurst, Clint

AU - Khunti, Kamlesh

AU - Liew, Adrian

AU - Michos, Erin D.

AU - Navaneethan, Sankar D.

AU - Olowu, Wasiu A.

AU - Sadusky, Tami

AU - Tandon, Nikhil

AU - Tuttle, Katherine R.

AU - Wanner, Christoph

AU - Wilkens, Katy G.

AU - Zoungas, Sophia

AU - Lytvyn, Lyubov

AU - Craig, Jonathan C.

AU - Tunnicliffe, David J.

AU - Howell, Martin

AU - Tonelli, Marcello

AU - Cheung, Michael

AU - Earley, Amy

AU - Rossing, Peter

PY - 2020/10

Y1 - 2020/10

N2 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeutics offer new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. An enlarging base of high-quality evidence from randomized clinical trials is available to evaluate important new treatments offering organ protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The goal of the new guideline is to provide evidence-based recommendations to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies. In addition, the guideline contains practice points to facilitate implementation when insufficient data are available to make well-justified recommendations or when additional guidance may be useful for clinical application. The guideline covers comprehensive care of patients with diabetes and CKD, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and self-management and health systems approaches to management of patients with diabetes and CKD.

AB - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeutics offer new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. An enlarging base of high-quality evidence from randomized clinical trials is available to evaluate important new treatments offering organ protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The goal of the new guideline is to provide evidence-based recommendations to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies. In addition, the guideline contains practice points to facilitate implementation when insufficient data are available to make well-justified recommendations or when additional guidance may be useful for clinical application. The guideline covers comprehensive care of patients with diabetes and CKD, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and self-management and health systems approaches to management of patients with diabetes and CKD.

KW - angiotensin II receptor blocker

KW - angiotensin-convering enzyme inhibitor

KW - chronic kidney disease

KW - dialysis

KW - evidence-based

KW - GLP-1 receptor agonist

KW - glycemia

KW - glycemic monitoring

KW - glycemic targets

KW - guideline

KW - HbA1c

KW - hemodialysis

KW - KDIGO

KW - lifestyle

KW - metformin

KW - models of care

KW - nutrition

KW - renin-angiotensin system

KW - self-management

KW - SGLT2 inhibitor

KW - systematic review

KW - team-based care

U2 - 10.1016/j.kint.2020.06.024

DO - 10.1016/j.kint.2020.06.024

M3 - Journal article

C2 - 32653403

AN - SCOPUS:85089856232

VL - 98

SP - 839

EP - 848

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -

ID: 257054337